Transcatheter aortic valve replacement: Protect the kidneys to protect the patient.
Vijay KumarAshok SethPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Transcatheter aortic valve replacement (TAVR) seems superior to surgical aortic valve replacement (SAVR) for intermediate-term outcomes in patients with aortic stenosis and moderate to severe chronic kidney disease (CKD). Intermediate-term mortality and the major adverse cardiac and renal event increase if the renal function worsens soon after TAVR or SAVR. Patient's demographic profile, comorbid conditions, and procedural characteristics influence the clinical outcomes emphasizing the need for careful risk assessment in deciding TAVR versus SAVR in CKD patient.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- aortic valve replacement
- aortic valve
- chronic kidney disease
- transcatheter aortic valve implantation
- ejection fraction
- left ventricular
- risk assessment
- end stage renal disease
- case report
- preterm infants
- type diabetes
- coronary artery disease
- emergency department
- high intensity
- cardiovascular events
- adipose tissue
- metabolic syndrome
- heart failure
- skeletal muscle
- early onset
- peritoneal dialysis
- preterm birth